Pfizer Tests The Luck Of The Irish; Will The US Let Its Pharma Pot Of Gold Go?
Pfizer and Allergan confirmed they are in friendly merger negotiations. Now the question is if Pfizer can afford to pay for Allergan and will the US government let a pharma giant the size of Pfizer go without a fight.
You may also be interested in...
Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.
Orna is retaining full ownership of its "crown jewel," in situ CAR programs for cancer. CEO Tom Barnes talked to Scrip about the deal and Orna's business strategy.
The pediatric market represents 70%-75% of the market for pneumococcal vaccines; Merck & Co.'s Vaxneuvance was already approved for infants earlier this year.